Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ryan, A. M.
Right arrow Articles by O'Neill, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryan, A. M.
Right arrow Articles by O'Neill, C. A.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Preclinical Safety Evaluation of rhuMAbVEGF, an Antiangiogenic Humanized Monoclonal Antibody

Anne M. Ryan

Departement of Pathology, Genentech, Inc., South San Francisco, Department of Pathology, MS 72 B, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, ryan.anne{at}gene.com.

Dorothy Bates Eppler

Department of Toxicology, Genentech, Inc., South San Francisco, California

Kelly E. Hagler

Departement of Pathology, Genentech, Inc., South San Francisco

Richard H. Bruner

Pathology Associates International, West Chester, Ohio

Peter J. Thomford

Covance Laboratories, Inc., Madison Wisconsin

Robert L. Hall

Covance Laboratories, Inc., Madison Wisconsin

George M. Shopp

Department of Toxicology, Genentech, Inc., South San Francisco, California, Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, California 94080.

Charles A. O'Neill

Department of Toxicology, Genentech, Inc., South San Francisco, California

Recombinant humanized antivascular endothelial growth factor (rhuMAbVEGF) is a monoclonal IgG, antibody that is being developed as an antiangiogenic agent for use in treating a variety of solid tumors. Preclinical safety studies included an immunohistochemical tissue cross-reactivity study, in vitro hemolytic potential and blood compatibility studies, and multiple dose toxicity studies. Toxicity studies were conducted in cynomolgus monkey because rhuMAbVEGF is pharmacologically active in this species and does not bind rat or mouse vascular endothelial growth factor (VEGF). Following twice weekly administration of rhuMAbVEGF for 4 or 13 wk, young adult cynomolgus monkeys exhibited physeal dysplasia characterized by a dose-related increase in hypertrophied chondrocytes, subchondral bony plate formation, and inhibition of vascular invasion of the growth plate. In addition, decreased ovarian and uterine weights and an absence of corpora lutea were observed in females receiving 10 and 50 mg/kg/dose in the 13-wk study. Both the physeal and ovarian changes were reversible with cessation of treatment. No other treatment-related effects were observed following rhuMAbVEGF administration at doses up to 50 mg/kg. These findings indicate that VEGF is required for longitudinal bone growth and corpora lutea formation and that rhuMAbVEGF can reversibly inhibit physiologic neovascularization at these sites.

Key Words: Growth plate • physis • vascular endothelial growth factor • angiogenesis • monoclonal antibody

References

  • Adamis AP, Shima DT, Tolentino M., Gragoudas E., Ferrara N., Folkman J., D'Amore PA, and Miller JW (1996). Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate. Arch. Ophthalmol. 114: 66-71.[Abstract/Free Full Text]
  • Aiello LP, Avery R., Arrigg R., Keyt B., Jampel H., Shah S., Pasquale L., Thieme H., Iwamoto M., Park JE, Nguyen H., Aiello LM, Ferrara N., and King GL (1994). Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N. Eng. J. Med. 331: 1480-1487.[Abstract/Free Full Text]
  • Alini M., Marriott A., Chen T., Abe S., and Poole AR (1996). A novel angiogenic molecule produced at the time of chondrocyte hypertrophy during endochondral bone formation. Dev. Biol. 176: 124-132.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Baird A. and Bohlen P. (1990). Fibroblast growth factors. In: Handbook of Experimental Pharmacology, MB Sporn and AB Roberts, (eds). Springer, Berlin, pp. 369-418.
  • Bassett Del (1943). The changes in the vascular pattern of the ovary of the albino rat during the estrus cycle. Am. J. Anat. 73: 251-278.[CrossRef][Web of Science]
  • Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A., Clark WC, Robertson JT, Ali IU, and Oldenfield EH (1993). Expression of the vascular permeability/vascular endothelial growth factor gene in central nervous system neoplasms. J. Clin. Invest. 91: 153-159.[Web of Science][Medline] [Order article via Infotrieve]
  • Berse B., Brown LF, Van de Water L., Dvorak HF, and Senger DR (1992). Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages and tumors. Mol. Biol. Cell 3: 211-218.[Abstract]
  • Borgström P., Hillan KJ, Sriramarao P., and Ferrara N. (1996). Complete inhibition of angiogenesis and growth of microtumors by antivascular endothelial growth factor neutralizing antibodies. Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56: 4032-4039.[Abstract/Free Full Text]
  • Brown LF, Berse B., Jackman RW, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, and Schnitt SJ (1995). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. 26: 86-91.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Brown LF, Berse B., Jackman RW, Tognazzi K., Manseau EJ, Dvorak HF, and Senger DR (1993). Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol. 143: 1255-1262.[Abstract]
  • Brown LF, Berse B., Jackman RW, Tognazzi K., Manseau EJ, Senger DR, and Dvorak HF (1993). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 53: 4727-4735.[Abstract/Free Full Text]
  • Brown LF, Berse B., Tognazzi K., Manseau EJ, Van de Water L., and Senger DR (1992). Vascular cell permeability factor mRNA and protein expression in the human kidney. Kidney Int. 42: 1457-1461.[Web of Science][Medline] [Order article via Infotrieve]
  • Carmeliet P., Ferreria V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., and Nagy A. (1996). Abnormal blood vessels development and lethality in embryos lacking a single VEGF allele. Nature (Lond.) 380: 435-439.[CrossRef][Medline] [Order article via Infotrieve]
  • Carter P., Presta L., Gorman CM, Ridgway Jbb, Henner D., Wong Wlt, Rowland AM, Knotts C., Carver ME, and Shepard HM (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89: 4285-4289.[Abstract/Free Full Text]
  • Center for Biologics Evaluation and Research, Food and Drug Administration (1997). Points to consider in the manufacture and testing of monoclonal antibody products for human use. CBER, Food and Drug Administration, Washington, D.C.
  • de Vries C., Escobedo JA, Ueno H., Houck K., Ferrara N., and Williams LT (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991.[Abstract/Free Full Text]
  • Detmar M., Brown LF, Claffey KP, Yeo KT, Kocher O., Jackman RW, Berse B., and Dvorak HF (1994). Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J. Exp. Med. 180: 1141-1146.[Abstract/Free Full Text]
  • Dvorak HF, Brown LF, Detmar M., and Dvorak AM (1995). Vascular permeability factor/vascular endothelial growth factor, microvascular permeability and angiogenesis. Am. J. Pathol. 146: 1029-1039.[Abstract]
  • Eigenbrot C., Gonzales T., Mayeda J., Carter P., Werther W., Hotaling T., Fox JA, and Kessler J. (1994). X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD-18 antibody: Structural indications of the key role of VH residues 59-65. Proteins 18: 49-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Eigenbrot C., Randal M., Presta L., and Kossiakoff AA (1993). X-ray structure of the antigen-binding domain from 3 variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J. Mol. Biol. 229: 969-995.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fava RA, Olsen NJ, Spencer-Green G., Yeo T-K., Yeo K-T., Berse B., Jackman RW, Senger DR, Dvorak HF, and Brown LF (1994). Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid arthritis. J. Exp. Med. 180: 340-346.
  • Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea KS, Powell-Braxton L., Hillan KJ, and Moore MW (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (Lond) 380: 439-442.[CrossRef][Medline] [Order article via Infotrieve]
  • Ferrara N., Chen H., Davis-Smyth T., Gerber HP, Nguyen T-N., Peers D., Chisholm V., Hillan KJ, and Schwall RH (1998). Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 4: 336-340.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ferrara N. and Davis-Smyth T. (1997). The biology of vascular endothelial growth factor. Endocr. Rev. 18: 425.
  • Ferrara N. and Henzel WJ (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161: 851-858.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ferrara N., Leung DW, and Phillips HS (1991). Molecular characterization and distribution of vascular endothelial growth factor. In: Neuroendocrine Perspectives, RB McClead and EE Muller, (eds). Springer/Verlag, New York, pp. 127-150.
  • Ferrara N., Winer J., and Burton T. (1991). Aortic smooth muscle cells express and secrete vascular endothelial growth factor. Growth Factors 5: 141-148.[Medline] [Order article via Infotrieve]
  • Folkman J. and Shing Y. (1992). Angiogenesis. J. Biol. Chem. 267: 10931-10934.[Free Full Text]
  • Garner A. (1994). Vascular diseases. In: Pathobiology of Ocular Diseases. A Dynamic Approach, A Garner and GK Klintworth, (eds). Marcel Dekker, New York, pp. 1625-1710.
  • Hanahan D. (1997). Signaling vascular morphogenesis and maintenance. Science 277: 48-50.[Free Full Text]
  • Houck KA, Ferrara N., Winer J., Cachianes G., Li B., and Leung DW (1991). The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5: 1806-1814.[Abstract/Free Full Text]
  • Houck KA, Leung DW, Rowland AM, Winer J., and Ferrara N. (1992). Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267: 26031-26037.[Abstract/Free Full Text]
  • Hunziker EB, Schenk RB, and Cruz-Orive L-M. (1987). Quantitation of chondrocyte performance in growth plate cartilage during longitudinal bone growth. J. Bone Joint Surg. 69A: 162-173.[Abstract/Free Full Text]
  • Iannotti JP (1990). Growth plate physiology and pathology. In: Pathologic Fractures in Metabolic Bone Disease, The Orthopedic Clinics of North America, Philadelphia, pp. 1-17.
  • Jakeman LB, Altar CA, Winer J., Bennett G., and Ferrara N. (1992). Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J. Clin. Invest. 89: 244-253.[Web of Science][Medline] [Order article via Infotrieve]
  • Jakeman LB, Armanini M., Phillips HS, and Ferrara N. (1993). Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 133: 848-859.[Abstract/Free Full Text]
  • Jones PT, Dear PH, Foote J., Neuberger MS, and Winter G. (1986). Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (Lond) 321: 522-525.[CrossRef][Medline] [Order article via Infotrieve]
  • Kamat BR, Brown LF, Manseau EJ, Senger DR, and Dvorak HF (1995). Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Am. J. Pathol. 146: 157-165.[Abstract]
  • Kaplan SL and Grumbach MM (1990). Pathophysiology and treatment of sexual precocity. J. Clin. Endocrinol. Metab. 71: 785-789.[Abstract/Free Full Text]
  • Kim KJ, Li B., Houck K., Winer J., and Ferrara N. (1992). The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7: 53-64.[Medline] [Order article via Infotrieve]
  • Kim KJ, Li B., Winer J., Armanini M., Gillett N., Phillips HS, and Ferrara N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (Lond) 362: 841-844.[CrossRef][Medline] [Order article via Infotrieve]
  • Kitamoto Y., Tokunaga H., and Tomita K. (1997). Vascular endothelial growth factor is an essential molecule for mouse kidney development: Glomerulogenesis and nephrogenesis. J. Clin. Invest. 99: 2351-2357.[Web of Science][Medline] [Order article via Infotrieve]
  • Klagsbrun M. and D'Amore PA (1991). Regulators of Angiogenesis. Annu. Rev. Physiol. 53: 217-239.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Klagsbrun M. and Smith S. (1980). Purification of a cartilage-derived growth factor. J. Biol. Chem. 255: 10859-10866.[Abstract/Free Full Text]
  • Koch AE, Harlow L., Haines GK, Amento EP, Unemori EN, Wong W-L., Pope RM, and Ferrara N. (1994). Vascular endothelial growth factor: A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. 152: 4149-4155.[Abstract]
  • Leung DW, Cachianes G., Kuang W-J., Goeddel DV, and Ferrara N. (1989). Vascular endothelial growth factor, a secreted angiogenic mitogen. Science 246: 1306-1309.[Abstract/Free Full Text]
  • Lobb R., Sasse J., Sullivan R., Shing Y., D'Amore P., Jacobs J., and Klagsbrun M. (1986). Purification and characterization of heparin-binding endothelial cell growth factors. J. Biol. Chem. 261: 1924-1928.
  • Lopez PF, Sippy BD, Lambert HM, Thach AB, and Hinton DR (1996). Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 37: 855-868.[Abstract/Free Full Text]
  • Maisonpierre PC. Suri C. Jones PF. Bartunkova S., Weigand SJ, Radziejewski C., Compton D. McClain J., Aldrich TH, Papadopoulos N., Daly TJ, Davis S. Sato TN, and Yancopoulos GD (1997). Angiopoietin-2, a natural antagonist for Tie 2 that disrupts in vivo angiogenesis. Science 277: 55-60.[Abstract/Free Full Text]
  • Mattern J., Koomagi R., and Volm M. (1996). Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma. Br. J. Cancer. 73: 931-934.[Web of Science][Medline] [Order article via Infotrieve]
  • McFarland CD, Brown RA, McLaughlin B., Ali SY, and Weiss JB (1990). Production of an endothelial cell stimulating angiogenesis factor (ESAF) by chondrocytes during in vitro cartilage calcification. Bone Miner. 11: 319-333.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Melnyk O., Schuman MA, and Kim KJ (1996). Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res. 56: 921-924.[Abstract/Free Full Text]
  • Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller Nph, Risau W., and Ullrich A. (1993). High affinity VEGF binding and developmental expression suggest fik-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835-846.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Miller RA, Oseroff AR, Stratte PT, and Levy R. (1983). Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62: 988-995.[Abstract/Free Full Text]
  • Minchenko A., Bauer T., Salceda S., and Caro J. (1994). Hypoxic stimulation of vascular endothelial growth factor expression in vivo and in vitro. Lab. Invest. 71: 374-379.[Web of Science][Medline] [Order article via Infotrieve]
  • Monacci WT, Merrill MJ, and Oldfield EH (1993). Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am. J. Physiol. 264: 995-1002.
  • Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, and Rabbits TH (1985). A hapten-specific chimeric IgE antibody with human physiological effector function. Nature (Lond) 314: 268-270.[CrossRef][Medline] [Order article via Infotrieve]
  • Park JE, Keller GA, and Ferrara N. (1993). The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of ECM-bound VEGE Mol. Biol. Cell 4: 1317-1326.[Abstract]
  • Plate KH, Brier G., Weich HA, and Risau W. (1992). Vascular endothelial growth factor is a potent tumor angiogenesis factor in human gliomas in vivo. Nature (Lond) 359: 845-847.[CrossRef][Medline] [Order article via Infotrieve]
  • Presta LG, Chen H., O'Connor SJ, Chisholm V., Meng YG, Krummen L., Winkler M., and Ferrara N. (1997). Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57: 4593-4599.[Abstract/Free Full Text]
  • Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, and Jardieu PM (1993). Humanization of an antibody directed against IgE. J. Immunol. 151: 2623-2632.[Abstract]
  • Ravindranath N., Little-Ihrig L., Phillips HS, Ferrara N., and Zeleznik AJ (1992). Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology 131: 254-260.[Abstract/Free Full Text]
  • Reichman L., Clark M., Waldmann H., and Winter G. (1988). Reshaping human antibodies for therapy. Nature (Lond) 332: 323-327.[CrossRef][Medline] [Order article via Infotrieve]
  • Schroff RW, Foon KA, Beatty SM, Odham RK, and Morgan AC Jr (1985). Human anti-murine immunoglobulin response in patients receiving monoclonal antibody therapy. Cancer Res. 45: 879-885.[Abstract/Free Full Text]
  • Senger DR, Galli S., Dvorak AM, Perruzzi CA, Harvey VS, and Dvorak HF (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascities fluid. Science 219: 983-985.[Abstract/Free Full Text]
  • Shima DT, Gougos A., Miller JW, Tolentino M., Robinson G., Adamis AP and D'Amore PA (1996). Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fasicularis. Invest. Ophthalmol. Vis. Sci. 37: 1334-1340.[Abstract/Free Full Text]
  • Shiraishi S., Nakagawa K., Kinukawa N., Nakano H., and Sueishi K. (1996). Immunohistochemical localization of vascular endothelial growth factor in human placenta. Placenta 17: 111-121.[Web of Science][Medline] [Order article via Infotrieve]
  • Shweiki D., Itin A. Soffer D., and Keshet E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond) 359: 843-845.[CrossRef][Medline] [Order article via Infotrieve]
  • Sierra-Honigmann MR, Nath AK, Murakami C., Garcia-Cardena G., Papapetropoulos A., Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, and Flores-Riveros JR (1998). Biological action of leptin as an angiogenic factor. Science 281: 1683-1686.[Abstract/Free Full Text]
  • Sullivan R. and Klagsbrun M. (1985). Purification of cartilage derived growth factor by heparin affinity chromatography. J. Biol. Chem. 260: 2399-2403.[Abstract/Free Full Text]
  • Terman BI, Dougher-Vermazen M., Carrion ME, Dimitrov D., Armellino DC, Gospodarowicz D., and Bohlen P. (1992). Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187: 1579-1586.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Torry DS, Holt VJ, Keenan JA, Harris G., Caudle MR, and Torry RJ (1996). Vascular endothelial growth factor expression in cycling human endometrium. Fertil. Steril. 66: 72-80.[Web of Science][Medline] [Order article via Infotrieve]
  • Trueta J. and Amato VP (1960). The vascular contribution to osteogenesis. III. Changes in growth cartilage caused by experimentally induced ischemia. J. Bone Joint Surg. 42B: 571-587.
  • Vaisman N., Gospodarowicz D., and Neufeld G. (1990). Characterization of the receptors for vascular endothelial growth factor. J. Biol. Chem. 265: 19461-19466.[Abstract/Free Full Text]
  • Warren RS, Yuan H., Matli MR, Gillett NA, and Ferrara N. (1995). Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95: 1789-1797.[Web of Science][Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 27, No. 1, 78-86 (1999)
DOI: 10.1177/019262339902700115
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
S. Patyna, C. Arrigoni, A. Terron, T.-W. Kim, J. K. Heward, S. L. Vonderfecht, R. Denlinger, S. E. Turnquist, and W. Evering
Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors
Toxicol Pathol, December 1, 2008; 36(7): 905 - 916.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
L J Singerman, H Masonson, M Patel, A P Adamis, R Buggage, E Cunningham, M Goldbaum, B Katz, and D Guyer
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial
Br J Ophthalmol, December 1, 2008; 92(12): 1606 - 1611.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. L. G. Bender, P. C. Adamson, J. M. Reid, L. Xu, S. Baruchel, Y. Shaked, R. S. Kerbel, E. M. Cooney-Qualter, D. Stempak, H. X. Chen, et al.
Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study
J. Clin. Oncol., January 20, 2008; 26(3): 399 - 405.
[Abstract] [Full Text] [PDF]

Home page
 ReproductionHome page
J Sengupta, P G L Lalitkumar, A R Najwa, D S Charnock-Jones, A L Evans, A M Sharkey, S K Smith, and D Ghosh
Immunoneutralization of vascular endothelial growth factor inhibits pregnancy establishment in the rhesus monkey (Macaca mulatta)
Reproduction, June 1, 2007; 133(6): 1199 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
K. Frazier, R. Thomas, M. Scicchitano, R. Mirabile, R. Boyce, D. Zimmerman, E. Grygielko, J. Nold, A.-C. DeGouville, S. Huet, et al.
Inhibition of ALK5 Signaling Induces Physeal Dysplasia in Rats
Toxicol Pathol, February 1, 2007; 35(2): 284 - 295.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. L. Martin, Q. Jiao, J. Cornacoff, W. Hall, B. Saville, J. A. Nemeth, A. Schantz, M. Mata, H. Jang, A. A. Fasanmade, et al.
Absence of Adverse Effects in Cynomolgus Macaques Treated with CNTO 95, a Fully Human Anti-{alpha}v Integrin Monoclonal Antibody, Despite Widespread Tissue Binding
Clin. Cancer Res., October 1, 2005; 11(19): 6959 - 6965.
[Abstract] [Full Text] [PDF]

Home page
 International Journal of ToxicologyHome page
J. Gaudreault, V. Shiu, A. Bricarello, B. J. Christian, C. L. Zuch, and B. Mounho
Concomitant Administration of Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin: Nonclinical Safety and Pharmacokinetics
International Journal of Toxicology, September 1, 2005; 24(5): 357 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
A. P. Brown, C. L. Courtney, L. M. King, S. C. Groom, and M. J. Graziano
Cartilage Dysplasia and Tissue Mineralization in the Rat Following Administration of a FGF Receptor Tyrosine Kinase Inhibitor
Toxicol Pathol, June 1, 2005; 33(4): 449 - 455.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. R. Wedge, J. Kendrew, L. F. Hennequin, P. J. Valentine, S. T. Barry, S. R. Brave, N. R. Smith, N. H. James, M. Dukes, J. O. Curwen, et al.
AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer
Cancer Res., May 15, 2005; 65(10): 4389 - 4400.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
P. van Wijngaarden, D. J. Coster, and K. A. Williams
Inhibitors of Ocular Neovascularization: Promises and Potential Problems
JAMA, March 23, 2005; 293(12): 1509 - 1513.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
H.-P. Gerber and N. Ferrara
Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies
Cancer Res., February 1, 2005; 65(3): 671 - 680.
[Abstract] [Full Text] [PDF]

Home page
 Cold Spring Harb Symp Quant BiolHome page
J.S. RUDGE, G. THURSTON, S. DAVIS, N. PAPADOPOULOS, N. GALE, S.J. WIEGAND, and G.D. YANCOPOULOS
VEGF Trap as a Novel Antiangiogenic Treatment Currently in Clinical Trials for Cancer and Eye Diseases, and VelociGene(R)- based Discovery of the Next Generation of Angiogenesis Targets
Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 411 - 418.
[Abstract] [PDF]

Home page
 Endocr. Rev.Home page
N. Ferrara
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Endocr. Rev., August 1, 2004; 25(4): 581 - 611.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. S. Beebe, J. P. Jani, E. Knauth, P. Goodwin, C. Higdon, A. M. Rossi, E. Emerson, M. Finkelstein, E. Floyd, S. Harriman, et al.
Pharmacological Characterization of CP-547,632, a Novel Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for Cancer Therapy
Cancer Res., November 1, 2003; 63(21): 7301 - 7309.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Harris, O. Kecha, C. Deal, C. R. Howlett, D. Deiss, V. Tobias, J. Simoneau-Roy, and J. Walker
Reversible Metaphyseal Dysplasia, a Novel Bone Phenotype, in Two Unrelated Children with Autoimmunepolyendocrinopathy-Candidiasis-Ectodermal Dystrophy: Clinical and Molecular Studies
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4576 - 4585.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
N. Ferrara, G. Frantz, J. LeCouter, L. Dillard-Telm, T. Pham, A. Draksharapu, T. Giordano, and F. Peale
Differential Expression of the Angiogenic Factor Genes Vascular Endothelial Growth Factor (VEGF) and Endocrine Gland-Derived VEGF in Normal and Polycystic Human Ovaries
Am. J. Pathol., June 1, 2003; 162(6): 1881 - 1893.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. E. Burkhardt, A. M. Ryan, and P.-G. Germann
Practical Aspects of Discovery Pathology
Toxicol Pathol, January 1, 2002; 30(1): 8 - 10.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
D. J. George, S. Halabi, T. F. Shepard, N. J. Vogelzang, D. F. Hayes, E. J. Small, and P. W. Kantoff
Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480
Clin. Cancer Res., July 1, 2001; 7(7): 1932 - 1936.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
N. Ferrara
Role of vascular endothelial growth factor in regulation of physiological angiogenesis
Am J Physiol Cell Physiol, June 1, 2001; 280(6): C1358 - C1366.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H.-P. Gerber, J. Kowalski, D. Sherman, D. A. Eberhard, and N. Ferrara
Complete Inhibition of Rhabdomyosarcoma Xenograft Growth and Neovascularization Requires Blockade of Both Tumor and Host Vascular Endothelial Growth
Cancer Res., November 1, 2000; 60(22): 6253 - 6258.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. R. Wedge, D. J. Ogilvie, M. Dukes, J. Kendrew, J. O. Curwen, L. F. Hennequin, A. P. Thomas, E. S. E. Stokes, B. Curry, G. H. P. Richmond, et al.
ZD4190: An Orally Active Inhibitor of Vascular Endothelial Growth Factor Signaling with Broad-Spectrum Antitumor Efficacy
Cancer Res., February 1, 2000; 60(4): 970 - 975.
[Abstract] [Full Text]

Home page
 J. Cell Sci.Home page
M. Carlevaro, S Cermelli, R Cancedda, and F Descalzi Cancedda
Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during endochondral bone formation
J. Cell Sci., January 1, 2000; 113(1): 59 - 69.
[Abstract] [PDF]

Home page
 Toxicol PatholHome page
A. M. Ryan
Commentary: Role of the Pathologist in the Identification and Characterization of Therapeutic Molecules
Toxicol Pathol, July 1, 1999; 27(4): 474 - 476.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ryan, A. M.
Right arrow Articles by O'Neill, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryan, A. M.
Right arrow Articles by O'Neill, C. A.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?